⚡️🇺🇸#JNJ #отчетность
Johnson & Johnson Reports Third Quarter 2021 Results
- Revenue: $23.34B (est $23.74B)
- Adj EPS: $2.60 (est $2.36)
- Covid-19 Vaccine Revenue 502M (est 761.8M)
- Sees adj FY Adj EPSceutical Sales $12.99B
- Sees FY Adj EPS $9.77-$9.82, Saw $9.60-$9.70, (est $9.66)
#прогноз Johnson & Johnson Increasing 2021 Full-Yr Guidance